Key result
Persistent MRA crescent sign over 5 mm is linked to ~24-fold higher delayed thromboembolic events.
Why the study?
The association of crescent signs with delayed thromboembolic events after changes in antiplatelet medication following stent-assisted coil embolization was unclear.
Is the presence of a crescent sign on follow-up MRA associated with delayed thromboembolic events after changes in antiplatelet medication in patients who underwent stent-assisted coil embolization for unruptured intracranial aneurysms?
Observational (n=63)
No
Is the presence of a crescent sign on follow-up MRA associated with delayed thromboembolic events after changes in antiplatelet medication in patients who underwent stent-assisted coil embolization for unruptured intracranial aneurysms?
Answers are grounded in this paper and cite their sources.
Persistent crescent signs >5 mm on follow-up MRA after stent-assisted coil embolization of intracranial aneurysms are associated with delayed thromboembolic events upon cessation or alteration of antiplatelet therapy, suggesting a need for continued dual antiplatelet treatment.
ObjectiveWe aimed to determine the "significant crescent signs" associated with delayed thromboembolic events (DTE) after changes in antiplatelet medication and to evaluate their incidence and natural course. MethodsBetween April 2009 and April 2011, 105 consecutive patients underwent stent-assisted coil embolization for unruptured intracranial aneurysms (n=107) in a single tertiary hospital.Sixty-three cases fulfilled the inclusion criteria and were included in this study.Crescent sign was evaluated through follow-up magnetic resonance angiography (MRA) immediately (<48 hours), 6 to 12 months, 1 to 2 years, and 2 to 4 years and correlated with the occurrence of DTE. ResultsCrescent signs were identified in 26 (41.3%) of 63 cases on immediate follow-up MRA.During the mean radiological follow-up of 53 months, the crescent signs (larger than 5 mm in length) persisted for more than 1 year in 11 (42.3%) of 26 cases.The crescent signs on follow-up MRA showed decreased size in 10 of 26 cases and disappeared in 5 cases.DTE occurred in 6 (9.5%) of 63 cases.In these 6 cases, all DTE occurred when the antiplatelet regimen was changed or stopped.Five of these six cases exhibited a crescent sign measuring over 5 mm in length, at the time of stroke. ConclusionsCrescent signs may be associated with DTE.When crescent signs are larger than 5 mm in length and continuously identified on follow-up MRA, continued dual antiplatelet treatment is required.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) conducted an observational in Unruptured distal internal carotid artery aneurysms (n=63). Persistent crescent sign (>5 mm) on MRA vs. No or minimal crescent sign (<5 mm) was evaluated on Delayed thromboembolic events (DTE) (p=0.001). A persistent crescent sign measuring over 5 mm on follow-up MRA was significantly associated with a higher incidence of delayed thromboembolic events compared to no or minimal crescent sign (45.5% vs 1.9%, p=0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: